@article{astmh:/content/journals/10.4269/ajtmh.16-0600,
author = "Ridley, David B.",
title = "Priorities for the Priority Review Voucher",
journal= "The American Journal of Tropical Medicine and Hygiene",
year = "2017",
volume = "96",
number = "1",
pages = "14-15",
doi = "https://doi.org/10.4269/ajtmh.16-0600",
url = "http://www.ajtmh.org/content/journals/10.4269/ajtmh.16-0600",
publisher = "The American Society of Tropical Medicine and Hygiene",
issn = "0002-9637",
type = "Journal Article",
abstract = "Abstract
The U.S. Congress created the priority review voucher program in 2007 to encourage development of drugs for neglected diseases. Under the voucher program, the developer of a drug for a neglected or rare pediatric disease that is approved by the U.S. Food and Drug Administration receives a bonus priority review voucher for another drug. As of 2016, four vouchers have sold for an average price of $200 million. Recent experience with the voucher program indicates strengths and weaknesses of the program, as well as a need for legislative changes.",
}